You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Follicular lymphomas (FL)

Showing 26 - 50 of 1,772
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Relapsed or Refractory (R/R) Follicular Lymphoma (FL), DLBCL (DLBCL) Trial (Odronextamab)

Available
  • Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • (no location specified)
Nov 8, 2022

B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2) Trial in Worldwide

Completed
  • B-cell Lymphomas (Phase 1)
  • +5 more
  • Birmingham, Alabama
  • +51 more
Dec 8, 2021

Follicular Lymphoma Trial in Worldwide (Ibrutinib, Rituximab)

Active, not recruiting
  • Follicular Lymphoma
  • Feldkirch, Austria
  • +41 more
Jul 1, 2022

Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)

Recruiting
  • Follicular Lymphoma
  • München, Bavaria, Germany
  • +39 more
May 19, 2022

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma

Recruiting
  • Anaplastic Large Cell Lymphoma
  • +19 more
  • Duarte, California
  • +2 more
Aug 15, 2022

CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Mantle Cell Lymphomas Trial in Philadelphia (Pembrolizumab)

Completed
Has Results
  • CD19+ Diffuse Large B-cell Lymphomas
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jul 20, 2021

Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC) Trial in Russian

Recruiting
  • Small Cell Lung Cancer (SCLC)
  • +2 more
  • Tucson, Arizona
  • +62 more
Jan 18, 2023

Follicular Lymphoma Trial in United States (DRL_RI (Proposed rituximab biosimilar), MabThera®)

Active, not recruiting
  • Follicular Lymphoma
  • DRL_RI (Proposed rituximab biosimilar)
  • MabThera®
  • Whittier, California
  • +3 more
May 27, 2022

Lymphoma, Follicular Trial in China (Abexinostat)

Recruiting
  • Lymphoma, Follicular
  • Beijing, China
  • +25 more
Mar 3, 2022

Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
  • Routine care as per site standard.
  • (no location specified)
Sep 15, 2023

Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) Trial in Worldwide (AMG 562)

Completed
  • Diffuse Large B-cell Lymphoma(DLBCL)
  • +2 more
  • AMG 562
  • Duarte, California
  • +11 more
Feb 22, 2022

Relapsed Follicular Lymphoma Trial in Italy (ZEVALIN, BEAM)

Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Genova, GE, Italy
  • +37 more
Dec 22, 2022

Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

Completed
Has Results
  • Marginal Zone Lymphoma
  • +2 more
  • Harbin, Heilongjiang, China
  • +3 more
Oct 26, 2021

Non-Hodgkin's Lymphoma Trial in Australia, Italy, United States (Obinutuzumab, Rituximab, Polatuzumab Vedotin)

Completed
  • Non-Hodgkin's Lymphoma
  • Tucson, Arizona
  • +22 more
Aug 5, 2022

Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United

Recruiting
  • Relapsed Chronic Lymphocytic Leukemia
  • +4 more
  • Phoenix, Arizona
  • +7 more
Apr 28, 2022

Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection,

Recruiting
  • Follicular Lymphoma and Marginal Zone Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62 Injection
  • Lenalidomide
  • Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Jun 15, 2021

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL) Trial in

Recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • +5 more
  • WZTL002-1 (1928T2z CAR-T cells)
  • Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
  • Wellington, New Zealand
    Wellington Hospital, Capital & Coast District Health Board
Feb 18, 2020

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +23 more
Dec 28, 2022

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Lymphoma Trial in Worldwide (Nivolumab)

Completed
Has Results
  • Lymphoma
  • Phoenix, Arizona
  • +44 more
Dec 13, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory DLBCL Trial in Spain, United Kingdom, United States

Completed
  • Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Marietta, Georgia
  • +27 more
Feb 4, 2022